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Graphene oxide (GO), an oxidised form of graphene, is widely used for biomedical applications, 
due to its dispersibility in water and simple surface chemistry tunability. In particular, small 
(less than 500 nm in lateral dimension) and thin (1-3 carbon monolayers) graphene oxide 
nanosheets (s-GO) have been shown to selectively inhibit glutamatergic transmission in 
neuronal cultures in vitro and in brain explants obtained from animals injected with the 
nanomaterial. This raises the exciting prospect that s-GO can be developed as a platform for 
novel nervous system therapeutics. It has not yet been investigated whether the interference of 
the nanomaterial with neurotransmission may have a downstream outcome in modulation of 
behaviour depending specifically on the activation of those synapses. To address this problem 
we use early stage zebrafish as an in vivo model to study the impact of s-GO on nervous system 
function. Microinjection of s-GO into the embryonic zebrafish spinal cord selectively reduces 
the excitatory synaptic transmission of the spinal network, monitored in vivo through patch 
clamp recordings, without affecting spinal cell survival. This effect is accompanied by a 
perturbation in the swimming activity of larvae, which is the locomotor behaviour generated by 
the neuronal network of the spinal cord. Such results indicate that the impact of s-GO on 
glutamate based neuronal transmission is preserved in vivo and can induce changes in animal 
behaviour. These findings pave the way for use of s-GO as a modulator of nervous system 
function. 
 










Graphene is a two-dimensional nanomaterial characterized by a honeycomb-lattice structure 




graphene’s tunable properties 1,2 have garnered interest as a tool for biomedical applications 
3,4,5,6,7. These include the development of neuronal implants and biodevices in the field of 
neuroscience research and medicine 8,9. A particular derivative of graphene, called graphene 
oxide (GO), which contains carbon, oxygen and hydrogen in variable ratios has attracted a lot 
of attention for healthcare applications 3, mainly due to its facile aqueous dispersion and the 
availability of C-O groups. Recent in vitro studies of neuronal cultures have shown that small 
lateral dimension GO (s-GO, with lateral size of less than 500 nm and thickness of 1-3 carbon 
monolayers), can modify synaptic activity without affecting neuronal survival 10. In this study, 
chronic s-GO treatment induced a specific downregulation of excitatory glutamatergic 
transmission in cultured rat hippocampal neurons 10 and reduced glutamate content in synaptic 
vesicles 10,11. More recently, the ability of s-GO in promoting a significant reduction in 
excitatory synaptic transmission was detected also in hippocampal explants obtained from 
animals injected 48 hours before with the nanomaterial 12.  
The potential of s-GO to downregulate excitatory transmission raises the exciting prospect that 
these materials can be exploited for treatment of disorders involving a pathological increase in 
glutamate synaptic transmission. Glutamate is the main excitatory neurotransmitter of the 
vertebrate brain 13 and excessive glutamate signalling can result in excitotoxicity 14. Indeed, 
glutamate excitotoxicity has been implicated in the pathogenesis of many neurological 
disorders including Huntington’s, Parkinson’s and Alzheimer’s disease, epilepsy, amyotrophic 
lateral sclerosis, pain and anxiety disorders 14,15,16,17,18,19. However, before the therapeutic 
potential of this material can be determined, its effects on neurotransmission at glutamatergic 
synapses must be validated in vivo by valuing also its possible impact on behaviour that relies 
on the activation of those synapses. To this end, we have used larval zebrafish as an in vivo 
model for studying the effect of nanomaterials on glutamate based synaptic communication. 
Furthermore, we investigated the impact of s-GO on the locomotor behaviour that correlates 




Early stage zebrafish are ideally suited for this purpose as they are amenable to a broad range 
of in vivo methodologies, including patch clamp electrophysiology, confocal imaging and 
behavioural analysis 20,21. In addition, the accessibility and relative simplicity of the zebrafish 
spinal cord 22 coupled with detailed knowledge of spinal neuron anatomy and function 
23,24,25,26,27,28 makes this an attractive system for exploring the effect of carbon-based 
nanomaterials on synaptic function and behaviour.  
Here we show that s-GO nanosheets delivered to the spinal cord of zebrafish larvae were able 
to selectively reduce spinal glutamatergic transmission in vivo without affecting neuronal 
survival. Patch clamp recordings performed in vivo two days after intra-spinal delivery of s-GO 
resulted in a strong reduction in glutamate release at excitatory synapses of spinal motor 
neurons. Such phenomenon was detected also during fictive swimming (that is the spinal 
electrical activity that correlates with bouts of locomotor behaviour in paralysed fish) in terms 
of a decrease in glutamatergic inputs received by motor neurons. These effects were 
accompanied by a decrease in the locomotor performance during behavioural experiments. 
Moreover, the observed changes were specific for s-GO, since the treatment with defects-free 
graphene (dfG) of similar size did not affect synaptic transmission or locomotor behaviour of 
injected larvae, suggesting that the effect may be related to the specific surface chemistry and 
dimensionality of s-GO. Our results provide the first demonstration that s-GO, by interfering 
with synaptic signalling of the brain region where they are delivered in vivo, can be used as a 





2.1. Characterization of nanomaterials 




s-GO were synthesized using a modified Hummers approach (see Supporting Information), 
following previously established protocols to ensure the production of endotoxin-free 
dispersions 10,29,30. The resulting s-GO dispersion had a brownish colour and showed good 
colloidal stability in aqueous media, as well as chemical stability at room temperature for more 
than 6 months. The physicochemical characterization of s-GO has already been reported 
elsewhere 30 and is summarized in Table 1 and in Supplemental Figure 1a, c. Morphology of 
s-GO nanosheets was examined by transmission electron microscopy (TEM) and atomic force 
microscopy (AFM), showing that the average lateral dimensions of s-GO are between 150-200 
nm. Flakes were determined to be 1-3 layers thick (Table 1 and Supplemental Figure 1a, c).  
dfG were produced by liquid-phase exfoliation of graphite 33 in water, using 1-pyrenesulfonic 
acid sodium salt as stabilizer 32. The dfG dispersions in aqueous media were homogeneous, of 
black colour, and stable at room temperature for at least 6 months. The physicochemical 
characterization of the dfG dispersions has already been reported elsewhere 32 and is 
summarized in Table 1 and in Supplemental Figure 1b, d. Structural properties were studied 
by TEM and AFM, showing that the average lateral dimensions of dfG are between 50 – 500 
nm (Table 1 and Supplemental Figure 1b, d), which are comparable to s-GO. Thickness of 
the flakes was found to be between 1 and 20 layers, using the AFM data and assuming a nominal 
thickness of ~5 nm, considering the layer of absorbed molecules on both sides of the graphene 
nanosheet 32. 
2.2. dfG and s-GO do not affect zebrafish development, neuronal survival or the passive 
electrical properties of motor neurons 
To determine the biocompatibility of graphene-based materials in vivo, a saline solution 
containing 0.5 ng of dfG or s-GO was microinjected into the spinal cord of zebrafish at two 
days post fertilization (dpf; Figure 1a). For controls, age-matched fish from the same clutch 
were microinjected with saline solution. Two days after injection, larval development was 




maturation 34 (Figure 1b). Fish injected with dfG and s-GO appeared morphologically identical 
to controls (Figure 1c) and exhibited no statistically significant variation in total body length 
(control: 3.5 ± 0.1 mm, n=10 fish; dfG-injected: 3.4 ± 0.1 mm, n=11 fish; s-GO-injected: 3.6 ± 
0.1 mm, n=10 fish), height measured at the level of the urogenital pore (control: 0.22 ± 0.01 
mm, dfG-injected: 0.20 ± 0.01 mm and s-GO-injected: 0.23 ± 0.01 mm), yolk sac diameter 
(control: 0.50 ± 0.02 mm, dfG-injected: 0.48 ± 0.02 mm, and s-GO-injected: 0.49 ± 0.01 mm) 
or eye size (control: 0.29 ± 0.01 mm, dfG-injected: 0.26 ± 0.01 mm and s-GO-injected: 0.27 ± 
0.01 mm; P values > 0.05, Figure 1d). Thus, injection of these materials did not grossly impact 
morphological development. 
We next assessed the effect of nanomaterials on neuron survival (Figure 1e). To do this, 
transgenic fish that selectively express GFP in motor neurons (Tg(hb9:GFP)) 35, glycinergic 
(Tg(glyT2:GFP)) or glutamatergic interneurons (Tg(VGLUT2A:GFP)) 36  were injected with 
control or nanomaterial-containing solution. Two days after injection, the number of GFP-
positive neurons was quantified in two segments of the spinal cord around the site of injection. 
The mean number of motor neurons did not significantly differ between control, dfG and s-GO 
injected larvae (control: 119 ± 6 cells, n=11 fish, dfG-injected: 118 ± 6 cells, n=12 fish and s-
GO-injected: 113 ± 3 cells, n=15 fish; P value > 0.05, Figure 1f). Similarly, no differences 
were observed in the number of inhibitory glycinergic (control: 91 ± 4 cells, n=7 fish, dfG-
injected: 81 ± 3 cells, n=7 fish and s-GO-injected: 84 ± 5 cells, n=7 fish) or excitatory 
glutamatergic (control: 129 ± 10 cells, n=9 fish, dfG-injected: 126 ± 15 cells, n=7 fish and s-
GO-injected: 136 ± 11 cells, n=7 fish) interneurons among the different treatments (P>0.05). 
These observations strongly suggest that nanomaterial injection did not modify survival of 
neurons in the zebrafish spinal cord. 
Next, we performed patch clamp electrophysiology of GFP-labelled motor neurons to 




(Figure 1g). We targeted specifically primary motor neurons for this purpose, as these have 
well-characterized and stereotyped soma size, soma position and axonal morphology 37,38. 
When comparing control (n=19 cells), dfG-injected (n=11 cells) and s-GO-injected (n=20 cells) 
fish (Figure 1h), no statistically significant difference in cell capacitance (control: 20 ± 1 pF, 
dfG-injected: 17 ± 1 pF; s-GO-injected: 19 ± 1 pF, P>0.05), input resistance (control: 126 ± 10 
MΩ; dfG-injected: 169 ± 19 MΩ; s-GO-injected: 145 ± 14 MΩ, P>0.05) or resting membrane 
potential (control: -70 ± 1 mV; dfG-injected: -69 ± 1 mV; s-GO-injected: -68 ± 1 mV, P>0.05) 
was observed. Therefore, these basic indicators of neuronal maturation and health 39,40,41 are not 
changed by exposure to nanomaterials. In summary, these results suggest that the direct 
microinjection of the two types of graphene-based nanomaterials did not affect the development, 
gross morphology of zebrafish and had no effect on the survival and basic physiological 
properties of motor neurons. 
2.3. s-GO selectively reduce glutamatergic synaptic transmission  
We next studied the effect of s-GO and dfG on synaptic glutamatergic and glycinergic 
transmission in the spinal cord. To this end, we injected fish with nanomaterials and, after a 
two-days incubation period, conducted whole cell patch clamping of primary motor neurons 
(using the experimental setting shown in Figure 1g). We began by analysing miniature 
postsynaptic currents (mPSCs) in the presence of tetrodotoxin (1 µM), a Na+ channel blocker 
that abolishes spike-dependent transmission. Under this condition, neurotransmitter containing 
vesicles are released stochastically from the presynaptic terminal, making neurotransmitter 
molecules available in the synaptic cleft to bind their receptors expressed on postsynaptic 
membrane. The properties of mPSCs can be used to derive information about the synapse 
structural and functional characteristics: changes in mPSCs frequency are usually related to 
modifications in the presynaptic release probability and/or in the number of synaptic contacts, 




Glutamatergic (glut-) mPSCs were pharmacologically isolated by bath application of picrotoxin 
(50 μM) and strychnine (1 µM), which block GABAergic and glycinergic currents respectively 
(Figure 2a). Analysis revealed a significant reduction in the frequency of glut-mPSCs in s-GO 
injected fish (1.0 ± 0.2 Hz, n=20 cells, P=0.024) when compared to control fish (2.0 ± 0.4 Hz, 
n=19 cells). However, the amplitude (control: 12 ± 1 pA and s-GO-injected: 10 ± 1 pA), rise 
time (control: 0.28 ± 0.01 ms and s-GO-injected: 0.31 ± 0.02 ms) and decay time (control: 0.87 
± 0.04 ms and s-GO-injected: 0.90 ± 0.04 ms) of glu-mPSCs were not affected (P>0.05). The 
finding was specific for s-GO, as fish injected with dfG exhibited no changes in glut-mPSCs 
frequency (1.4 ± 0.4 Hz), amplitude (14 ± 2 pA) or kinetics (rise time was 0.31 ± 0.02 ms and 
decay time was 1.08 ± 0.11 ms, n=11 cells) when compared to controls (all P > 0.05, Figure 
2b).  
Next, inhibitory glycinergic synaptic transmission was analysed by monitoring glycinergic 
(glyc-) mPSCs, recorded in the presence of picrotoxin (50 μM) to block GABAergic currents 
and kynurenic acid (2.5 mM) to block glutamatergic currents (Figure 2c). We observed no 
changes in the frequency of glyc- mPSC in either s-GO (3.9 ± 0.5 Hz, n=15 cells) or dfG 
injected fish (3.2 ± 0.5 Hz, n=11 cells) when compared to controls (3.5 ± 0.5 Hz, n= 14 cells; 
P>0.05; Figure 2d). In addition, glyc- mPSC amplitudes (control: 33 ± 4 pA, dfG -injected: 34 
± 6 pA and s-GO-injected: 31 ± 4 pA), rise times (control: 0.43 ± 0.02 ms, dfG -injected: 0.4 ± 
0.01 ms and s-GO-injected: 0.47 ± 0.03 ms) and decay times (control: 2.8 ± 0.3 ms, dfG -
injected: 3.1 ± 0.3 ms and s-GO-injected: 3.4 ± 0.4 ms) did not significantly differ between 
treatment groups (P>0.05, Figure 2c,d).  In sum, these findings suggest that s-GO, but not dfG, 
selectively depresses glutamatergic signalling in the zebrafish spinal cord.   
2.4. s-GO impair glutamatergic drive to motor neurons during fictive swimming 
To determine if s-GO also impaired glutamatergic signalling during locomotor-related network 




that correlates with bouts of locomotor behaviour in paralysed fish) was recorded (as shown in 
Figure 1g).  
During fictive swimming, motor neurons receive synaptic drive from glutamatergic and 
glycinergic neurons, which generates volleys of combined excitatory and inhibitory currents 
42,43 (Figure 3a). To study these current components, we voltage clamped primary motor 
neurons at the chloride and cationic reversal potentials to isolate glutamatergic and glycinergic 
currents respectively 43,44.  
During bouts of fictive swimming recorded from s-GO injected fish (Figure 3b), we observed 
a reduction in the total area of the excitatory glutamatergic drive (control: 22722 ± 5434 pA*ms, 
n=19 cells; s-GO-injected: 9037 ± 1360 pA*ms, n=18 cells; P=0.031, Figure 3d) that was 
coupled with a decrease in the frequency (control: 24.0 ± 6 Hz; s-GO-injected: 7 ± 1.5 Hz; 
P=0.013) and amplitude (control: 16 ± 2 pA; s-GO-injected: 10 ± 1 pA; P=0.04) of 
glutamatergic currents during bouts of locomotor drive. These modifications were specifically 
induced by s-GO, as animals injected with dfG showed no statistically significant difference in 
these parameters with respect to controls (area: 10071 ± 1448 pA*ms; glutamatergic PSC 
frequency: 23 ± 8 Hz; tonic current amplitude: 15 ± 2 pA; n=9 cells, P values > 0.05). By 
contrast, the duration of bouts of excitatory drive (control: 1.25 ± 0.21 s; dfG -injected: 0.75 ± 
0.12 s; s-GO-injected: 1.06 ± 0.14s) and the amplitude of glutamatergic postsynaptic currents 
(control: 20 ± 3 pA, dfG -injected: 18 ± 3 pA; s-GO-injected: 16 ± 2 pA) were similar among 
the different groups (P>0.05, Figure 3d). These findings strongly suggest that s-GO, but not 
dfG, decrease the glutamatergic drive to motor neurons during fictive swimming. 
The chloride-mediated glycinergic drive was also isolated by voltage clamping motor neurons 
at the reversal potential for cationic currents (Figure 3c). In this case, no differences were 
detected in the area (control: 28557 ± 15391 pA*ms, n=19 cells; dfG-injected: 31280 ± 12067 
pA*ms, n=9 cells; s-GO-injected: 11727 ± 2621 pA*ms, n=18 cells; P>0.05) or duration 




bouts. Moreover, the amplitude (control: 56 ± 14 pA, dfG-injected: 53 ± 12 pA and s-GO-
injected: 45 ± 6 pA,) and frequency (control: 33 ± 3 Hz, dfG -injected: 40 ± 9 Hz and s-GO-
injected: 30 ± 5 Hz; P values>0.5, Figure 3e) of glycinergic PSCs during swim bouts was also 
not affected. Overall, these results point out that the glutamatergic, but not the glycinergic, 
locomotor drive to primary motor neurons is significantly reduced in zebrafish treated with s-
GO. 
2.5. s-GO injections in the spinal cord of the zebrafish impair locomotor performance 
 The analysis of synaptic drive to motor neurons during fictive swimming revealed that the 
excitatory inputs to motor neurons were depressed in s-GO injected fish. This suggested that 
intra-spinal delivery of this nanomaterial might also modify locomotor activity. This hypothesis 
was tested in two sets of behavioural experiments in which spontaneous and stimulus-evoked 
locomotor responses were analysed two days after treatment. 
During spontaneous swimming tests (Figure 4a), fish treated with s-GO exhibited a marked 
reduction in the total distance swum (110 ± 12 mm, n=16 fish) in comparison to controls (378 
± 83 mm, n=11 fish; P=0.0013; Figure 4a, b). This effect was mainly due to a statistically 
significant decrease in the length of the single bouts of swimming (control: 0.45 ± 0.04 s; s-
GO-injected: 0.30 ± 0.03 s; P=0.022), while the percentage of time spent active over the 5 min 
recording period was not changed between the different treatments (control: 20.6 ± 5.7%; s-
GO-injected: 7.5 ± 1.6%; P>0.05). Remarkably, dfG-treated larvae did not show any 
statistically significant difference in their locomotor activity with respect to controls (swim 
distance was 237 ± 65 mm, bout length was 0.35 ± 0.03 s and the percentage of motor activity 
was 15.7 ± 4.0%, n=13 fish; P values>0.5, Figure 4a, b). 
Startle-evoked locomotor responses were elicited by applying an acoustic stimulation to the 
recording chamber (Figure 4c). In all the three conditions (control, dfG and s-GO treatments), 
fish showed a robust locomotor response immediately after the stimulus. However, locomotor 




p=0.046) and distance travelled (control: 44 ± 13 mm; s-GO-injected: 9 ± 2 mm; p=0.044, 
Figure 4c, d) were decreased in fish injected with s-GO. By contrast, dfG injected fish did not 
exhibit statistically significant changes in these parameters (4.25 ± 1.47 s and 27 ± 7 mm, n=13 
fish; P>0.05). The averaged velocity of swimming (calculated over the time of effective 
swimming) was comparable among the three groups (control: 5.6 ± 1.2 mm/s; dfG-injected: 8.1 
± 1.6 mm/s and s-GO-injected: 5.7 ± 1.3 mm/s; P>0.05). 
These findings indicate that swimming performance is markedly reduced in zebrafish treated 
with s-GO and, when considered in light of our electrophysiological results, are likely to arise 
from an impairment of the glutamatergic drive to motor neurons. 
2.6. Graphene-based nanomaterials can be detected in the spinal cord after injection 
We attempted to determine the presence of nanomaterials within the spinal cord of injected 
zebrafish. Both dfG and s-GO can be readily imaged when dispersed in saline solution using 
bright field light microscopy (Figure 5a, left panels for each nanomaterial). However, due to 
the low intensity of contrast between the carbon backbone and the biological substrate, this 
technique is not informative to study nanomaterials in biological tissue. We therefore exploited 
the optical properties of both types of graphene-based materials to investigate their localization 
in zebrafish in vivo. dfG of larger size and thickness were visualized by reflected light imaging 
acquisition mode 11, while s-GO were previously intracellularly tracked, utilizing their intrinsic 
fluorescent properties by confocal fluorescence microscopy 45. The right panels of Figure 5a 
show for each material how it appears when visualized in saline solution using these different 
imaging techniques. 
Two days after the intra-spinal direct microinjection, zebrafish treated with dfG were scanned 
in vivo, both in fluorescence and reflective modes. Using reflection microscopy approaches, 
dfG were observed in the spine at around the site of delivery, indicating that at least the larger 
dfG flakes and their aggregates were still in locus two days after the post-injection (Figure 5b). 




this approach, we were unable to detect s-GO in the spinal cord 2 days after injection (Figure 
5c).  Nonetheless, 1 day after the treatment the presence of the s-GO nanosheets was observed 
at the site of injection within the spinal cord (Figure 5d).  
3. Discussion 
We report here the ability of s-GO nanosheets to modulate zebrafish spinal glutamatergic 
synapses and correlated locomotor behaviour in vivo. Remarkably, the effect was specific for 
this type of graphene-based material, since dfG with similar lateral dimensions did not induce 
any statistically significant modification in the electrical activity of spinal synapses, as well as 
in the behaviour of injected larvae with respect to controls. Our findings point towards a specific 
downregulation of synaptic signalling at glutamatergic synapses targeting motor neurons, as 
demonstrated by the decrease in excitatory mPSCs frequency. This effect was also manifested 
as a reduction in the glutamatergic drive for locomotion during in vivo bouts of fictive 
locomotion. Such phenomenon did not appear to stem from a general perturbation of neuronal 
membrane properties as basic electrophysiological parameters of the neurons were not changed, 
reflecting neuronal health and membrane integrity 39,40,41. In addition, the density of motor 
neurons, excitatory and inhibitory interneurons monitored by analysing the number of GFP 
positive cells in the site of the injection in different types of transgenic fish (Tg(hb9:GFP), 
Tg(GlyT2:GFP) and Tg(VGlut2A:GFP)) was not altered, demonstrating that s-GO do not affect 
neuronal survival. 
The decrease in the frequency, but not in the amplitude, of glut-mPSCs observed in s-GO 
treatment is commonly associated with changes at the pre-synaptic loci 46. These observations 
stand in broad agreement with previous studies carried on in vitro 10,11 and on brain explants 
obtained from animals injected with s-GO 12, demonstrating a depression in glutamate vesicular 
release following s-GO exposure. One possible explanation for this effect is that nanomaterials 
in the synaptic cleft might trap glutamate releasing vesicles in an open state, preventing the re-




would be expected to result in depletion of vesicles from the presynaptic terminal. This would 
account for the reduction in excitatory synaptic drive during recordings of fictive locomotor 
activity 47. 
In contrast to our findings with s-GO, we observed no change in mPSC properties or locomotor-
related synaptic signalling following dfG spinal cord injection. Although investigation of the 
mechanisms underlying the interaction between s-GO and synaptic vesicles is beyond the scope 
of this study, we can speculate that the differential effects between these nanomaterials might 
arise from slight differences in shape and thickness which in turn would affect nanoparticle–
membrane interactions 48. In addition, the thinner, more hydrophilic character of s-GO, 
presenting many more oxygen-rich surface functionalities, not only favours the dispersibility 
of the nanosheets in saline solution 49, but also allows for more complex interactions with 
neuronal components (ion channels, clefts), and in particular those at the plasma membrane. 
Our behavioural studies detected a diminished locomotor performance in zebrafish treated with 
s-GO, both in free and evoked swimming tests. It is unlikely that this effect arises from a 
developmental delay as the quantitative analysis of anatomical features commonly used as 
indicators of zebrafish development 34, suggested that s-GO injection did not perturb 
development. Alterations in neuronal growth are also unlikely as electrophysiological passive 
properties of neurons were not affected by s-GO injection 39,40,41. 
Therefore, the observed reduction in locomotor activity of s-GO-injected larvae stems from a 
decreased excitatory drive to motor neurons in the spinal network. Assuming that integrative 
properties of motor neurons are not modified, the s-GO induced reduction of excitatory drive, 
in the presence of no changes in the inhibitory inputs, is expected to lead to decrease in motor 
neuron drive, which in turn will decrease activation of muscle fibers. This is compatible with 
the reduction in the locomotor performance observed in our behavioural studies. Remarkably, 
the analysis of free swimming activity has revealed a reduction in the length of single swimming 




Similarly, stimulus-evoked startle responses appeared shorter in duration and distance covered 
in animals treated with s-GO. We speculate that such behaviour might correlate with a reduced 
availability of glutamate in the pre-synaptic terminal. 
Our results might appear in contrast with recent works reporting developmental neurotoxic 
effects of graphene oxide in zebrafish larvae and embryos 50,51,52. However, differences in the 
characteristics of the used nanomaterial (e.g. the lateral size), in its preparation method or in 
the modality of zebrafish exposure might be reponsible for such diverse outcome. A detailed 
physico-chemical characterization of nanomaterials, as the one we reported here, is 
fundamental for understanding the biological effect of specific types of nanostructured 
materials53. 
In relation to a previous report where the impairment of rat excitatory synapses due to in vivo 
s-GO exposure was shown 12, our findings offer new knowledge on how s-GO interference with 
glutamatergic synapses in a specific brain region can result in modulation of animal behaviour 
that relies on the activity of that neuronal network. In our model neuronal activity from an intact 
spinal network connected with other regions of the nervous system (e.g. sensory system) was 
recorded in an in vivo setting. This allowed a more comprehensive understanding of the effect 
of nanomaterials on neuronal network signals ongoing in vivo (fictive swimming) and driving 
locomotor behaviour. 
Fluorescence and light-reflective microscopy is a reliable qualitative technique to image 
graphene-based nanomaterials in biological tissue 11,45,54 and through these approaches we 
attempted to detect the presence of dfG and s-GO sheets in zebrafish in vivo post-injection. At 
two days post-injection, when s-GO mediated electrophysiological and behavioural effects 
were observed, we could image dfG, but not s-GO locally. Nevertheless, we were able to detect 
the presence of s-GO in the spinal cord 24 hours after the injection. This finding confirms that 
s-GO were effectively delivered to the spinal cord and localized within the nervous system for 




stages. This could be because s-GO diffused, or were actively cleared, from the site of injection, 
resulting in levels of concentration or focal aggregation that fell beyond the limits of detection 
for the microscopic technique used (spatial resolution in the range of 1-2 µm for intact zebrafish 
55,56). Our electrophysiological experiments were not able to dissect if the observed reduction 
in excitatory signalling resulted from the direct presence of s-GO in the spinal cord, (but at low, 
undetectable, concentration), or if two days after injections the nanomaterial was completely 
cleared. In this last hypothesis, the decrease in excitatory transmission could arise from the 
effect of s-GO during the maturation of synaptic circuitry, resulting in the consolidation of 
glutamatergic synapses with a reduced release of neurotransmitter from presynaptic terminals.  
Future investigations will be required to validate this possibility. 
4. Conclusion 
We have shown here that intra-spinally injected s-GO in zebrafish depress glutamatergic 
transmission in vivo and result in modifications of animal behaviours which are associated with 
neuronal network activity of the spinal cord. These findings, considered in conjunction with 
previous reports of the s-GO effect observed in rat hippocampal and cortical preparations 10,11,12 
suggest that these thin nanosheets can induce inhibition of glutamatergic signalling ubiquitously 
across brain circuits and animal species. Such findings may pave the way towards the 
translation of s-GO in therapy for the treatment of human nervous system diseases in which 
excitatory transmission is pathologically increased. 
5. Experimental  
Preparation and physicochemical characterization of s-GO and dfG:  Previously established 
protocols were used to produce s-GO 10,29,30 and dfG 32,33. A detailed description of these and 
the physicochemical characterization of the two nanomaterials are reported in Supporting 
Information.  
Intra-spinal delivery of nanomaterials: Zebrafish (D. rerio) were maintained and treated at the 
University of Leicester (UK) in accordance with the local, national (Animals Act 1986, 




university Animal Welfare and Ethical Review Body and by the Genetic Modification 
Committee. Zebrafish larvae aged 2 dpf were anesthetised with 0.02% MS222 (Sigma) and 
embedded 2% agarose.  Fine glass pipettes (diameter < 1 µm) were filled with control or 
nanomaterial containing solution which was then inserted into the 7th – 8th segments of the 
spinal cord using a 10X objective of an upright microscope equipped with epifluorescence 
system (Nikon, Eclipse FN1). Approximately 0.5 nl, corresponding to ~0.5 µg of nanomaterial 
containing solution was ejected from the pipette using a pressurized air microinjector 
(Picosprizter III, 12 ms duration, 10 PSI). Three solutions were used for injections: 1) control 
standard saline solution (Evan’s solution, whose composition is described below), 2) dfG 
containing solution (dissolved in saline solution at a concentration of 0.9 mg/ml) and 3) s-GO 
containing solution (dissolved in saline solution at a concentration of 0.9 mg/ml). A fluorescent 
dye (Alexa Fluor 488) was included in the injection solution to facilitate visualisation of the 
site of injection and the effective delivery of the solution.  
After injections, larvae were carefully removed from agar with fine forceps, immersed in 
Evan’s solution and allowed to recover in standard conditions (at 28.5°C on a 14:10 hour light : 
dark cycle) until reaching the age of 4 dpf. 
Morphological analysis of larvae: for morphological analysis, 4 dpf larvae were anesthetised 
with 0.02% of MS222 and fixed with PFA 4% (Sigma) for 90 min a room temperature. Fixed 
animals were put on a plastic dish in PBS and imaged with a microscope (Nikon 8M7800) 
interfaced to camera (Moticam 1000) and an acquisition software (Image Plus 2.0). The 
following anatomical traits were measured to evaluate the developmental stage: larvae length 
was the distance from the snout to the caudal peduncle. Larvae height was the distance from 
ventral to dorsal, defined ventrally by the confluence of the anterior margin of the anal fin, the 
posterior of the peritoneal cavity and the ventral margin of the myotomes. Eye diameter was 
the distance at the longest axis of the eye. Yolk diameter was the distance at the shorter axis of 




Confocal microscopy: to quantify neuron numbers transgenic zebrafish expressing GFP 
selectively in motor neurons, excitatory and inhibitory interneurons were used (Tg(hb9:GFP), 
Tg(glyT2:GFP) and Tg(VGLUT2A:GFP)) 35,36. Larvae at 4 dpf were fixed in PFA, rinsed in 
PBS and cleared in glycerol prior to mounting on microscopy slides. 
The spinal cord was imaged at a magnification of 40X on an Olympus FV1000 confocal laser 
scanning microscope using Fluoview FV1000 capture software and serial confocal planes were 
acquired every 0.5 μm across the spine of the fish. For imaging of GFP expression in neurons, 
an excitation wavelength of 488 nm and filters for an emission wavelength of 495-530 nm were 
used. Reconstructions of the images were performed offline using the image-processing 
package Fiji. The number of GFP positive motor neurons was counted from z-stack images 
using the Cell counter plugin for Fiji. For imaging of nanomaterials injected in the spinal cord, 
larvae were anesthetised with 0.02% of MS222, embedded in agar 2% and mounted on 
microscopy slides. Excitation/emission wavelengths for GFP was as reported above. Excitation 
wavelength for s-GO was 594 nm, while emission wavelength was 620–700 nm. The 
acquisition was performed in a sequential mode for the two channels. dfG were visualised by 
using the reflection mode property during the confocal acquisition. The same acquisition setting 
was used for nanomaterials injected fish and controls, to avoid artefactual signals. 
Electrophysiology: whole cell voltage clamp recordings were conducted in 4 dpf zebrafish 
larvae in vivo as previously described 42. After being anesthetized and paralyzed in  Evans 
physiological saline (134 NaCl, 2.9 KCl, 2.1 CaCl2, 1.2 MgCl2, 10 mM glucose and 10 HEPES, 
pH 7.8)  containing  0.02%  tricaine (MS-222), larvae were pinned on their side to  the  surface  
of  a  Sylgard-coated  plastic  petridish by pressing short pieces of fine tungsten wire through 
the notochord.  To expose the spinal cord, the skin between the two pins was removed using 
suction through a patch pipette with the tip diameter of ~50 µm.  Suction was used initially to 
remove the skin from the muscle underneath while the pipette was moved caudally over the 




accessible for a length of 2–3 somites. At this point, fish were perfused with Evans 
physiological saline containing the neuromuscular blocker D-tubocurarine (10 μM). All 
electrophysiological recordings were performed at room temperature. A cell body in the spinal 
cord was approached while a small amount of positive pressure in the patch pipette was applied, 
in order to break the dura overlying the spinal cord, leaving the naked cell body of neuron 
exposed to the pipette. 
Patch clamp recordings were performed from primary motor neurons of Tg(hb9:GFP) zebrafish 
larvae, which were identified by means of their GFP expression and their stereotyped cell-body 
positions and size 37. 
Patch electrodes, pulled from borosilicate glass capillaries (Harvard Apparatus, UK), with a 
resistance of 7-10 MΩ were used for electrophysiology recording. For most experiments, these 
were filled with intracellular solution containing (in mM) K gluconate 126, KCl 16, MgCl2 2, 
HEPES 10, EGTA 10 and Na2ATP 4 (pH 7.3). However, for recordings of glyc-mPSCs, a high 
chloride electrode solution was used that contained (in mM) CsCl 135, HEPES 10, EGTA 10, 
Na2ATP 2, MgCl2 2 (pH 7.3). Sulforhodamine B (0.1 %) was routinely added to the patch 
pipette solution to visualise neuronal morphology using fluorescence optics of the patch clamp 
microscope (Nikon FN-1). This permitted to confirm cell phenotype on the base of 
characteristic peripheral branching patterns 38. For all recordings, a patch-clamp amplifier 
(Multiclamp 700B, Axon Instruments, Sunnyvale, CA, USA) connected to an analog to digital 
converter (Digidata 1440A, Axon Instruments, Sunnyvale, CA, USA) was used to acquire 
electrophysiology data which were stored on a PC running pClamp 10, Axon Instruments, 
Sunnyvale, CA, USA). Raw signals were acquired at 10 kHz and filtered offline at 2 kHz. 
Liquid junction potential was of ∼13 mV (calculated with the Clampex software; Molecular 
Devices, Sunnyvale, CA, USA) and membrane potentials were corrected for it. 
Immediately after getting the whole cell configuration, resting membrane potentials were 




All the other measurements were carried out in voltage clamp mode. Glut-mPSCs and gly-
mPSCs were recorded from a holding potential of −70 mV in the presence of TTX (1 μM, to 
block sodium currents and propagated action potentials), picrotoxin (50 µM, to abolish GABAA 
receptor mediated currents), and either strychnine (1 μM, to block glycinergic currents) or 
kynurenic acid (2.5 mM, to block glutamatergic currents).  
To isolate excitatory inputs to primary motor neurons during fictive swimming, cells were 
clamped at the reversal potential of chloride (-46 mV), while to record inhibitory input, the 
holding potential was set at the reversal potential for cationic currents (~ +5 mV).  
The stability of the patch was checked by repetitively monitoring the input and series resistance 
during the experiments. Cells exhibiting 15% changes were excluded from the analysis. The 
series resistance was < 20 MΩ and it was not compensated.  
Electrophysiological data analysis: input resistance and cells capacitance were measured 
online with the membrane test feature of the pClamp software. 
For analysis of glut- and gly-mPSC, template matching functions 10,11,12 were used to isolate 
populations of events. The frequency of mPSCs was calculated as the number of events in a 
300-second period. For each recording, mPSCs were averaged, then the rise time (defined as 
the time taken by the current to go from the 10 % to the 90 % of the peak value), the decay time 
(corresponding to the time required by the current to decline from  the 90 % to 10 % of the peak 
value) and amplitude of mPSCs were examined in the resulting trace. The data obtained from 
different cells were averaged across each experimental condition. The decay phase of miniature 
PSCs was calculated from averaged traces by fitting it with a mono-exponential function. 
For the analysis of fictive swimming, the duration, the area and the amplitude of tonic current 
in episodes of excitatory and inhibitory drive were measured manually with cursors. 
Glutamatergic and glycinergic post synaptic currents (PSCs) during the episodes were detected 
using the template function of Clampfit and their frequency and amplitude were measured. For 




Drug Treatment: drugs were applied to the bath via a gravity-fed perfusion system. Drugs used 
were:  strychnine and picrotoxin, purchased from Sigma-Aldrich (UK), kynurenic acid and TTX 
from HelloBio (UK). Stock solutions were made in distilled water or in DMSO and then 
aliquoted and frozen at −20°C.  
Behavioural Experiments: for free swimming experiments, individual 4 dpf larvae were 
transferred to a recording chamber that contained an overhead camera and an infrared light 
source for illumination. Fish were allowed to acclimatize for 10 minutes before behaviour was 
recorded for a period of 5 minutes.  
To measure the startle response, after 5 minutes of acclimatization, escape swimming was 
elicited by applying an acoustic stimulation to the recording chamber. The acoustic stimulation 
was a computer generated sudden loud noise (1 tone at 500 Hz, lasting 1 second), played 
through a commercial loudspeaker, which was physically connected to the recording chamber. 
The sound intensity in proximity of the recording chamber was measured with a noise detector 
and was ~70 dB. 
Digital video (avi format) recordings were acquired at 15 frames per second using Flycap2 
software (Point Grey). Files were then processed in VirtualDub and converted to the micro fly 
movie format (ufmf) using any2ufmf (http://ctrax.sourceforge.net/any2ufmf.html) for 
subsequent analysis in California Institute of Technology Fly Tracker (Ctrax, v 0.2.16). The 
position and orientation of individual fish was quantified in a semi-automated manner by Ctrax. 
Errors in tracking were subsequently corrected using FixErrors in MatLab environment. The 
velocity of swimming and distance swum were extracted with this analysis. 
In addition, the number and the duration of beat/glide episodes during free swimming were 
measured by means of The Janelia Automatic Animal Behavior Annotator (JAABA; 
http://jaaba.sourceforge.net/).    
Statistics: the results are presented as the mean ± SE; n is the number of neurons for patch 




performed by using the software Prism GraphPad 8. Data were first tested for normality by 
using Shapiro-Wilk test. For parametric data, the statistically significant difference among the 
three groups was assessed through one-way ANOVA, using Tukey’s test for post hoc analysis. 
Not parametric data were analyzed with Kruskal-Wallis test and post hoc analysis was done 
with Dunn’ multiple comparison test. Reported P values are those calculated in the post hoc 
analysis. p < 0.05 was considered statistically significant. 
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Figure 1. Intra-spinal delivery of s-GO and dfG does not alter zebrafish development, neuronal 
survival or the electrophysiological basic properties of motor neurons. (a) Experimental setting 
for injections of nanomaterials in the spinal cord of 2 dpf zebrafish. Left: lateral view of a 2 dpf 
zebrafish larva; the rectangle indicates the region of the body targeted by injection. Middle: 




through a tiny glass pipette. Right: fluorescence field of the previous image, showing that the 
injected solutions, added with a fluorescent dye, are delivered precisely in the spinal cord. (b) 
Schematic representation of the anatomical traits measured in zebrafish to analyse their 
development. (c) Bright field images of control, dfG-injected and s-GO-injected fish two days 
after injection. (d) Plots reporting the values of fish length and height, eye and yolk diameters. 
(e) Confocal images (Z-stack reconstructions) of the spinal cord of control, dfG-injected and s-
GO-injected fish. Green signal is GFP expressed in motor neurons. (f) Plots reporting the 
number of motor neurons in the two segments of spinal cord around the site of injection. (g) 
Experimental setting for in vivo patch clamp recordings from motor neurons in zebrafish spinal 
cord: on the left a schematic representation of the patch clamp pipette inserted in the spinal cord 
(in red) of a larva, on the right bright field image of spinal neurons during recordings. A patch 
clamp pipette targeting the cell body of a motor neuron is visible. (h) Plots reporting the 
capacitance, the input resistance and the resting membrane potential of primary motor neurons. 

















Figure 2. Intra-spinal delivery of s-GO selectively impairs excitatory synapses. (a) Left 
panel: sample tracings of glut- mPSCs recorded in control, dfG-treated and s-GO-treated fish. 
Right panel: glut-mPSCs collected from each corresponding trace and superimposed. Bold trace 
is the resulting electronic average. (b)  Plots reporting the values of glut-mPSC frequency, 
amplitude, rise and decay time. c) Left panel: sample tracings of glyc- mPSCs recorded in 




corresponding trace and superimposed. Bold trace is the resulting electronic average. (b)  Plots 
reporting the values of glyc-mPSC frequency, amplitude, rise and decay time. Dots 
superimposed to bars correspond to single experiment values. s-GO treatment significantly 

















Figure 3. Intra-spinal delivery of s-GO decreases the excitatory drive to motor neurons 
during fictive swimming. Examples of traces recorded at -15 mV (a), -46 mV (b) and +5 mV 
(c) for control (left), dfG-injected (middle) and s-GO-injected (right) fish. (d) Plots reporting 
the values of episode area and duration, EPSC frequency and amplitude, and tonic current 
amplitude for the excitatory drive. s-GO treatment significantly decreased the episode area, 
EPSC frequency and the tonic current (*P<0.05). (e) Plots reporting the values of episode area 
and duration, IPSC frequency and amplitude, for the inhibitory drive. Dots superimposed to 







Figure 4. Effects of intra-spinal delivery of s-GO on zebrafish behaviour. (a) Left: bright 
field image of recording chamber for free swimming test. Right: swimming trajectories of 4 dpf 
control, dfG-injected and s-GO-injected zebrafish recorded over a 5 min period. (b) Plots 
reporting the values of the total distance swum, percentage of time spent swimming and 
swimming bout length. Dots superimposed to bars correspond to single experiments values. s-
GO treatment significantly decreased the total distance swum and the length of swimming bouts 
(*P<0.05). (c) Left, sketch of the experimental setting in startle response experiments. Right, 
swimming trajectories of 4 dpf control, dfG injected and s-GO-injected zebrafish swum after 
the application of an acoustic stimulus. (d) Plots reporting the values of the distance swum, the 
time spent swimming and the swimming velocity. s-GO treatment significantly decreased the 






Figure 5. Confocal microscopy of dfG and s-GO injected in the spinal cord of zebrafish. 
(a) Images of dfG and s-GO dispersed in saline solution. Left panels for each material are bright 
field images, while right panels are images in reflective mode for dfG and in fluorescence for 
s-GO. (b) Z-stack reconstructions of the spinal cord of control and dfG -injected fish, 2 days 
after treatment. Images, acquired in fluorescence and reflective modes sequentially, show the 
localization of dfG (red) in the spinal cord, which is identifiable thanks to the presence of GFP 
positive motor neurons (green). (c-d) Z-stack reconstructions of the spinal cord of control and 
s-GO-injected fish, 2 days (c) and 1 day (d) after treatment. Images, acquired in fluorescence 
mode sequentially for the red and green channels, show the localization of s-GO (red) in the 
spinal cord, which is identifiable thanks to the presence of GFP positive motor neurons (green), 
only 1 day after the injection (d), but not later (c). In d, below, magnification of the area in the 
square for s-GO injected fish. 
